SAFETY/IMMUNE RESPONSE TO DNA PLASMID VACCINE IN ASYMPTOMATIC HIV

无症状 HIV 患者对 DNA 质粒疫苗的安全性/免疫反应

• 批准号: 5216093
• 负责人: ROB R MACGREGOR
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5216093
• 关键词: AIDS education /prevention; AIDS therapy; AIDS vaccines; HIV infections; T lymphocyte; clinical research; clinical trial phase I; drug screening /evaluation; human subject; human therapy evaluation; immunity

The primary purpose of this project is to determine whether multiple intramuscular injections of the APL 400-003 HIV DNA plasmid vaccine at dose levels of 30, 100, and 300 micrograms can be administered safely to asymptomatic HIV-infected patients. As a secondary objective, the protocol is designed to evaluate whether these multiple intramuscular injections of the APL 400-003 Vaccine might enhance existing antigen-specific immune responses, especially T cell responses, when administered to asymptomatic HIV-infected patients and to characterize the immune response profile of these patients pre- and post-injection, and to monitor indicators of progression of HIV infection in these asymptomatic HIV-infected patients.

这个项目的主要目的是确定是否多重